Cancer Letters
Volume 286, Issue 1 , Pages 96-102 , 1 December 2009

Human hepatocellular carcinoma: Expression profiles-based molecular interpretations and clinical applications

  • Kam M. Hui

      Affiliations

    • Corresponding Author InformationTel.: +65 6436 8337; fax: +65 6226 3843.

Received 26 February 2008 ,Accepted 4 November 2008.

References 

  1. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis. 2006;27:2070–2082
  2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer. 2006;6:674–687
  3. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006;25:3778–3786
  4. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253–1267
  5. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353:1253–1257
  6. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002;8:816–824
  7. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576
  8. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005;9:191–211
  9. Kane MA. Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. Cancer Epidemiol. Biomarkers Prev. 2003;12:2–3
  10. Mann D, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer. 2007;43:979–992
  11. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  12. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 2007;356:11–20
  13. Wang S, Ooi L, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin. Cancer Res. 2007;13:6275–6283
  14. Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 2007;25:773–780
  15. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 2006;20:1839–1845
  16. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene. 2007;26:3629–3636
  17. Tan M, Ooi LL, Aw SE, Hui KM. Cloning and identification of hepatocellular carcinoma down-regulated mitochondrial carrier protein, a novel liver-specific uncoupling protein. J. Biol. Chem. 2004;279:45235–45244
  18. Liu BH, Goh C, Ooi LL, Hui KM. Identification of unique and common low abundance tumor-specific transcripts by suppression subtractive hybridization and oligonucleotide probe array analysis. Oncogene. 2008;27:4128–4136
  19. Tommasi S, Pinto R, Pilato B, Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr. Pharm. Des. 2007;13:3279–3287
  20. Chattopadhyay D, Manas DM, Reeves HL. The development of targeted therapies for hepatocellular cancer. Curr. Pharm. Des. 2007;13:3292–3300
  21. Arsura M, Cavin LG. Nuclear factor-kB and liver carcinogenesis. Cancer Lett. 2005;229:157–169
  22. Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod. Pathol. 2006;19:533–540
  23. Eichhorst ST. Modulation of apoptosis as a target for liver disease. Expert Opin. Ther. Targets. 2005;9:83–99
  24. Hui KM. Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma. Curr. Opin. Mol. Ther. 2007;9:378–384
  25. Sena-Esteves M, Saeki Y, Fraefel C, Breakefield XO. HSV-1 amplicon vectors-simplicity and versatility. Mol. Ther. 2000;2:9–15
  26. Nettelbeck DM, Jérôme V, Müller R. Gene therapy: designer promoters for tumour targeting. Trends Genet. 2000;16:174–181
  27. Michalopoulos GK. Liver regeneration. Cell. Physiol. 2007;213:286–300
  28. Wang GY, Ho IA, Sia KC, Miao L, Hui KM, Lam PY. Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. Hum Gene Ther. 2007;18:222–231
  29. Lam YP, Sia KC, Khong JK, Geest BD, Lim KS, Ho IA, et al. An efficient and safe Herpes Simplex Virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol. Ther. 2007;15:1129–1136
  30. Comijin J, Berx G, Vermassen P, Verschueren K, Grunsven L, Bruyneel E, et al. The two handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasions. Mol. Cell. 2001;7:1267–1278
  31. Tsopanomichalou M, Kouroumalis E, Ergazaki M, Spandidos DA. Loss of heterozygosity and microsatellite instability in human non-neoplastic hepatic lesions. Liver. 1999;19:305–311
  32. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004;303:1378–1381
  33. Kirk GD, Lesi OA, Mendy M, Szymanska K, Whittle H, Goedert JJ, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24:5858–5867
  34. Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J. Hepatol. 1997;27:661–668
  35. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin. Liver Dis. 2005;25:433–449
  36. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127:S79–S86
  37. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin. Liver Dis. 2001;21:57–69
  38. Klingenberg M. Uncoupling proteins-how do they work and how are they regulated. IUBMB Life. 2000;32:89–90
  39. Ramsey JJ, Harper ME, Weindruch R. Restriction of energy intake, energy expenditure, and aging. Free Radic. Biol. Med. 2000;29:946–968
  40. Mitchell P, Moyle J. Evidence discriminating between the chemical and the chemiosmotic mechanisms of electron transport phosphorylation. Nature. 1965;208:1205–1206
  41. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr. Mol. Med. 2007;7:121–131
  42. Modica-Napolitano JS, Aprille JR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv. Drug Deliv. Rev. 2001;49:63–70
  43. Morgan J, Oseroff AR. Mitochondria-based photodynamic anti-cancer therapy. Adv. Drug Deliv. Rev. 2001;49:71–86
  44. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J. Clin. Oncol. 2005;23:8093–8108
  45. Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, et al. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology. 2007;133:1475–1486
  46. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45:42–52

PII: S0304-3835(08)00873-2

doi: 10.1016/j.canlet.2008.11.005

Cancer Letters
Volume 286, Issue 1 , Pages 96-102 , 1 December 2009

Article Tools

* Image Usage & Resolution